Home › Funds › Madison Avenue Partners, LP › TBPH
Madison Avenue Partners, LP position in TBPH
THERAVANCE BIOPHARMA INC
Madison Avenue Partners, LP reported holding 9,212,252 shares of TBPH (THERAVANCE BIOPHARMA INC) in its Q2 2026 13F filing — a position valued at US$156.6M, representing 6.74% of its reported portfolio and ranking #6 among its reported holdings. Madison Avenue Partners, LP has disclosed TBPH holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Madison Avenue Partners, LP's TBPH position evolved
Madison Avenue Partners, LP first disclosed a stake in TBPH in Q3 2023 at 7,012,226 shares (US$60.5M). The position peaked in Q4 2025 at 9,511,150 shares, worth US$178.0M. Across 12 filings, Madison Avenue Partners, LP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 9,212,252 shares valued at US$156.6M — a reduction of -298,898 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 7.01M | $60.52M | New |
| Q4 2023 | 7.01M | $78.82M | Hold |
| Q1 2024 | 7.01M | $62.90M | Hold |
| Q2 2024 | 8.51M | $72.18M | Add |
| Q3 2024 | 9.51M | $76.66M | Add |
| Q4 2024 | 9.51M | $89.50M | Hold |
| Q1 2025 | 9.51M | $84.93M | Hold |
| Q2 2025 | 9.51M | $104.91M | Hold |
| Q3 2025 | 9.51M | $138.86M | Hold |
| Q4 2025 | 9.51M | $177.95M | Hold |
| Q1 2026 | 9.51M | $154.37M | Hold |
| Q2 2026 | 9.21M | $156.61M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TBPH and 13F data
TBPH (THERAVANCE BIOPHARMA INC) is a company whose sector is not yet classified in our data. 31 other funds we track also report a position in TBPH — the largest reported positions include Weiss Asset Management LP (US$126.8M), Newtyn Management, LLC (US$58.4M), Irenic Capital Management LP (US$46.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TBPH
- Weiss Asset Management LP 7.46M sh · $126.77M · Q2 2026
- Newtyn Management, LLC 3.43M sh · $58.38M · Q2 2026
- Irenic Capital Management LP 2.76M sh · $46.94M · Q2 2026
- Oasis Management Co Ltd. 583.49K sh · $9.92M · Q2 2026
More on Madison Avenue Partners, LP
FAQ
How long has Madison Avenue Partners, LP held TBPH?
Madison Avenue Partners, LP has disclosed TBPH holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Madison Avenue Partners, LP's current position in TBPH?
As of Q2 2026, Madison Avenue Partners, LP holds 9.21M shares of TBPH (THERAVANCE BIOPHARMA INC), valued at $156.61M, representing 6.74% of its reported portfolio and ranking #6.
Has Madison Avenue Partners, LP been buying or selling TBPH?
In the latest 13F filing (Q2 2026), Madison Avenue Partners, LP reduced its position in TBPH. The position peaked in Q4 2025 at 9.51M shares.
Which other funds hold TBPH?
Other major institutional holders of TBPH include Weiss Asset Management LP, Newtyn Management, LLC, Irenic Capital Management LP, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.